UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027

Annals of oncology, 2018-10, Vol.29, p.viii522-viii523

2018

Volltextzugriff (PDF)

EP12.01-03 Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S641

2023

Volltextzugriff (PDF)

EP12.03-03 A Case of Successful Desensitization Treatment with Tepotinib after Tepotinib-Induced Rash

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S680-S681

2023

Volltextzugriff (PDF)

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Journal of clinical oncology, 2020-01, Vol.38 (2), p.115-123

2020

Volltextzugriff (PDF)

1505TiP TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression

Annals of oncology, 2023-10, Vol.34, p.S847-S848

2023

Volltextzugriff (PDF)

EP1.01-99 Effect of Immune Checkpoint Inhibitors Re-Administration in Non-Small-Cell Lung Cancer Patients

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S952-S952

2019

Volltextzugriff (PDF)

Effect of Long-Term and Low-Dose Administration of Erythromycin on Proliferation of T Lymphocytes Stimulated with Mitogens

Journal of chemotherapy (Florence), 2008-10, Vol.20 (5), p.604-608

2008

Volltextzugriff (PDF)

330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure

Annals of oncology, 2022-11, Vol.33, p.S1572

2022

Volltextzugriff (PDF)

EP1.01-64 Effect of Amrubicin in Patients with Previously Treated Non-Small-Cell Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S937-S937

2019

Volltextzugriff (PDF)

Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study

Annals of oncology, 2017-11, Vol.28, p.x137-x137

2017

Volltextzugriff (PDF)

SIOG2024-4-OA-048 Enhancing geriatric assessment implementation in Japan: insights from the ENSURE-GA study

Journal of geriatric oncology, 2024-10, Vol.15 (7)

2024

Volltextzugriff (PDF)

EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S456-S457

2022

Volltextzugriff (PDF)

1445PA phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

Annals of oncology, 2019-11, Vol.30, p.ix157-ix158

2019

Volltextzugriff (PDF)

1525P - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

Annals of oncology, 2019-10, Vol.30, p.v626-v626

2019

Volltextzugriff (PDF)

A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401

Annals of oncology, 2019-10, Vol.30, p.v734-v735

2019

Volltextzugriff (PDF)

1557P - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-10, Vol.30, p.v641-v642

2019

Volltextzugriff (PDF)

A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-10, Vol.30, p.v641-v642

2019

Volltextzugriff (PDF)

1525PUpdated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1807PA randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1807P - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401

Annals of oncology, 2019-10, Vol.30, p.v734-v735

2019

Volltextzugriff (PDF)

Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

Annals of oncology, 2019-10, Vol.30, p.v626

2019

Volltextzugriff (PDF)

1557PA large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

Chest, 2019-08, Vol.156 (2), p.357-366

2019

Volltextzugriff (PDF)

A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

Annals of oncology, 2017-11, Vol.28, p.x129-x130

2017

Volltextzugriff (PDF)

1 – 25 von 1.138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(654)
Mit Volltextzugriff
(845)

Publikationsform

Sprache

Englisch
(916)
Japanisch
(277)
Polnisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027

EP12.01-03 Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study

EP12.03-03 A Case of Successful Desensitization Treatment with Tepotinib after Tepotinib-Induced Rash

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

1505TiP TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression

EP1.01-99 Effect of Immune Checkpoint Inhibitors Re-Administration in Non-Small-Cell Lung Cancer Patients

Effect of Long-Term and Low-Dose Administration of Erythromycin on Proliferation of T Lymphocytes Stimulated with Mitogens

330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure

EP1.01-64 Effect of Amrubicin in Patients with Previously Treated Non-Small-Cell Lung Cancer

Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study

SIOG2024-4-OA-048 Enhancing geriatric assessment implementation in Japan: insights from the ENSURE-GA study

EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

1445PA phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

1525P - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401

1557P - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC)

A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC)

1525PUpdated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

1807PA randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401

1807P - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401

Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

1557PA large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC)

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404

Suchergebnisse filtern